BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have been given an average rating of “Moderate Buy” by the twenty-three analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twenty have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $94.6316.

A number of brokerages have recently issued reports on BBIO. Raymond James Financial cut shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley upped their target price on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Canaccord Genuity Group started coverage on shares of BridgeBio Pharma in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price target for the company. Finally, Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a research note on Thursday, April 9th. They set an “outperform” rating and a $100.00 price target for the company.

BridgeBio Pharma Trading Up 1.2%

BBIO opened at $84.09 on Friday. The stock has a market cap of $16.47 billion, a PE ratio of -22.48 and a beta of 0.95. BridgeBio Pharma has a 1 year low of $42.09 and a 1 year high of $93.42. The stock’s 50 day simple moving average is $70.31 and its 200-day simple moving average is $72.18.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same period in the prior year, the business posted ($0.88) earnings per share. BridgeBio Pharma’s revenue for the quarter was up 66.8% compared to the same quarter last year. Equities analysts forecast that BridgeBio Pharma will post -2.3 earnings per share for the current fiscal year.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright lifted its earnings estimates for BridgeBio Pharma across multiple future periods, including FY2027 EPS to $2.19 from $2.12, while reiterating a Buy rating and a $120 price target. HC Wainwright raises BridgeBio Pharma price target to $120
• Positive Sentiment: HC Wainwright also raised its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 earnings estimates, reinforcing the view that BridgeBio’s earnings trajectory is improving. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: RBC Capital reaffirmed its Buy view on BridgeBio Pharma, adding to the overall positive analyst backdrop. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: A recent article noted BridgeBio could be a relative beneficiary after a competing biotech trial miss, which may have helped sentiment around the sector and the stock. Phase 3 failure sends biotech winners and losers in opposite directions
• Negative Sentiment: Director Andrea Ellis sold 17,167 shares, and another filing shows Director Jennifer E. Cook sold 148,589 shares, which can weigh on investor sentiment even though both trades were made under pre-arranged 10b5-1 plans. Insider selling at BridgeBio Pharma

Insiders Place Their Bets

In other news, Director Jennifer E. Cook sold 148,589 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total value of $13,156,070.06. Following the completion of the transaction, the director directly owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. This represents a 94.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $67.46, for a total value of $2,698,400.00. Following the transaction, the chief executive officer owned 535,686 shares of the company’s stock, valued at $36,137,377.56. This trade represents a 6.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 432,117 shares of company stock worth $32,633,740 in the last 90 days. 14.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BBIO. Harvest Fund Management Co. Ltd bought a new stake in shares of BridgeBio Pharma in the 3rd quarter worth about $34,000. Jones Financial Companies Lllp bought a new position in BridgeBio Pharma during the 1st quarter valued at about $35,000. Farther Finance Advisors LLC lifted its holdings in BridgeBio Pharma by 91.4% during the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. Global Retirement Partners LLC boosted its position in BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after buying an additional 372 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in BridgeBio Pharma in the fourth quarter valued at about $41,000. 99.85% of the stock is owned by institutional investors.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.